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Ganglioneurocytoma (central neurocytoma with diffuse ganglionic
differentiation) with neuraxis dissemination. 
Case report and review of the literature
Lucyna K´pka1, Douglas C. Miller2, Jacek Fijuth1
We report the case of a 46-year-old man with ganglioneurocytoma, initially managed by subtotal resection. The location of the
tumour was typical for central neurocytoma, but there was a rapid local progression (in 3 months) mimicking malignant
tumour with simultaneous dissemination in the brain as evidenced by magnetic resonance imaging (MRI). The histological
appearance of this tumour lacked features of malignancy and showed two neoplastic cells types – a predominance of neurocytes
with some ganglion cells scattered singly and in clusters in all parts of the tumour. An immunostain for synaptophysin was typ-
ical for neuronal tumours. The proliferative potential of the tumour was low, as indicated by an MIB1 immunostain. The dis-
ease was managed at progression with radiotherapy delivered to the whole brain (42 Gy in 15 fractions) and with a boost to
the primary site (2 fractions of 2 Gy). Four months after radiotherapy the neurological status of the patient had improved and
he no longer required steroid administration. MRI revealed tumour stabilisation. We conclude that neuronal tumours like gan-
glioneurocytoma or central neurocytoma with diffuse ganglionic differentiation may not be as benign as previously thought and
discuss other data reporting malignant behaviour of such tumours. Aggressive tumour behaviour can occur in the absence of
the described histopathological signs of poor prognosis, making clinical predictions from the pathological data uncertain. The
predictive value of the proliferative index, reported by some authors, is not always a reliable predictor of aggressive behaviour,
as exemplified by the case now reported.
Ganglioneurocytoma z rozsiewem w centralnym uk∏adzie nerwowym.
Opis przypadku i przeglàd piÊmiennictwa
Przedstawiono przypadek 46-letniego m´˝czyzny, u którego dokonano subtotalnej resekcji guza mózgu, zlokalizowanego
w okolicy otworu Monroe prawej komory bocznej. W badaniu histopatologicznym zdiagnozowano guz pochodzenia neuronal-
nego, z∏o˝ony z 2 typów komórek nowotworowych – neurocytów i komórek zwojowych. Ostatecznie postawiono rozpoznanie
histopatologiczne – ganglioneurocytoma. Na podstawie morfologii guza (brak atypii, pleomorfizmu, martwicy) oraz niskiego
potencja∏u proliferacyjnego, oznaczonego za pomocà przeciwcia∏ MIB1, okreÊlono, ˝e chodzi o wysokozró˝nicowany, dobrze
rokujàcy nowotwór. Stan ogólny i neurologiczny chorego uleg∏, w ciàgu 3 miesi´cy po zabiegu operacyjnym, znacznemu pogor-
szeniu. W rezonansie magnetycznym mózgu wykazano bardzo du˝à progresj´ miejscowà nowotworu, z jednoczesnym rozsie-
wem wzd∏u˝ komór, charakteryzujàcym si´ obecnoÊcià satelitarnych guzów w rogu skroniowym i potylicznym komory bocz-
nej prawej i jednoczesnym wzmocnieniem kontrastowym wzd∏u˝ komory III. W badaniu cytologicznym p∏ynu mózgowo-rdze-
niowego z punkcji l´dêwiowej nie znaleziono komórek nowotworowych. Chory zosta∏ napromieniony na mózg i C1-C2, do
dawki 42 Gy w 15 frakcjach, z podwy˝szeniem dawki na obszar wznowy miejscowej do 46 Gy. Cztery miesiàce po zakoƒcze-
niu radioterapii stwierdzono stabilizacj´ choroby w badaniu radiologicznym i lekkà popraw´ stanu neurologicznego.
Dokonano przeglàdu piÊmiennictwa dotyczàcego tego rzadkiego nowotworu. Zaznaczono, ˝e wed∏ug niektórych autorów, gan-
glioneurocytoma nie jest oddzielnà jednostkà chorobowà, lecz odmianà neurocytoma centrale ze znacznym rozleg∏ym ró˝ni-
cowaniem w kierunku gangliocytoma. Szybka progresja nowotworu z jednoczeÊnie stwierdzonym rozsiewem wzd∏u˝ uk∏adu
komorowego, chocia˝ niezgodna z opisem ∏agodnego nowotworu pochodzenia neuronalnego, nie stanowi wyjàtku. Istniejà
w piÊmiennictwie doniesienia o takiej w∏aÊnie ewolucji choroby. Nieznane sà czynniki rokownicze, które pozwoli∏yby przewi-
dzieç niekorzystny przebieg choroby. Podaje si´ w piÊmiennictwie, ˝e wysoki potencja∏ proliferacyjny nowotworu jest najwa˝-
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Introduction
The first recognition of intraventricular (central) neuro-
cytoma as a distinct clinicopathological entity appeared 20
years ago. Hassoun et al. described such neoplasms in
the region of the foramen of Monroe as a rather indolent
(“benign”) neuronal origin tumour developing in young
adults from the ventricular walls or septum pellucidum
[1]. Neurocytomas are composed of neurocytes – cells,
which while relatively small are not immature neurob-
lasts, (earlier case reports had described these tumors as
“differentiating intraventricular neuroblastomas”) [2] but
neither are they large ganglion cells; instead they are the
neoplastic counterparts of the small granular neurones
of the cerebellar cortex, dentate gyrus, or the second and
fourth neocortical laminae. To our knowledge, about 200
cases of neurocytoma have been published. Central neu-
rocytoma was listed in WHO CNS tumours classification
as a benign, grade I tumour [3]. Although benign biolog-
ical behaviour of this tumour is emphasised in most pub-
lications, many reports show a completely different char-
acter of its clinical course, with rapid recurrences and
even craniospinal dissemination [4-7]. Histopathological
variants, mainly with admixed ganglionic differentiation,
and sometimes with astrocytic differentiation, have also
been reported [7-9]. Whether extraventricular or
parenchymal neurocytic tumors are the same neoplasm
[10-12], as in the intraventricular examples, has been
a controversial issue, and need not be further discussed
herein.
We present a case of neurocytoma in its typical loca-
tion, but with a component of neoplastic ganglion-cell-like
cells allowing us to make a diagnosis of a combined
tumour – ganglioneurocytoma. Additionally, the pre-
sented case has shown a clinical course similar to the
malignant brain tumours with rapid local progression and
dissemination in the CNS.
Case report
P r e s e n t a t i o n  a n d  i n i t i a l  m a n a g e m e n t
A 46-year-old man presented with a one-week history of
generalized weakness. There was no significant past med-
ical history. Neurological examination showed no abnor-
malities, except for decreased strength in the upper and
lower extremities. CT brain scans showed a 6 cm (largest
diameter) tumour extending from the wall of the right
ventricle to the genu of the corpus callosum and the
region of the right basal ganglia. Compression of the ven-
tricle, midline shift and mild ventriculomegaly were also
present. Contrast enhancement was extensive and het-
erogeneous, mimicking a malignant tumour. The patient
underwent a removal of ventricular obstruction at the
foramen of Monroe and a subtotal resection of the
tumour under microscopic vision. The tumour extended
from the foramen of Monroe to the right fornix and into
the frontal horn of the right ventricle. Two days after the
first craniotomy the patient became slightly lethargic and
a CT brain scan showed increased size of the lateral right
ventricle. A right frontal ventriculostomy was placed. Ten
days later a ventriculoperitoneal shunt was created, which
was removed 15 days later because of infectious compli-
cations. The patient was fit to be discharged from the
hospital 1 month after the resection, in stable condition,
however with maintained generalized weakness.
Pa t h o l o g i c  f i n d i n g s
The tumour tissues were fixed in 10% buffered formalin,
processed routinely into paraffin. The sections were
stained with hematoxylin and eosin (HE), and with
immunohistochemical stains (for antibodies see Table I)
using standard avidin-biotin immunoperoxidase tech-
niques with diaminobenzidine as the final chromagen.
The tumour was a uniform neoplasm composed of two
admixed cell types: the first, and more numerous, pre-
sent at a moderate cell density and consisting of back-
to-back medium size cells with polygonal-to-round cell
bodies with clear cytoplasm and centrally placed bland
round nuclei (Figure 1A-B), and the second, less numer-
ous, large neuronal cells – ganglion cells – many of which
had peculiar shapes, cell bodies with eosinophillic cyto-
plasm pushing the Nissi granules peripherally, and rarely,
two nuclei (Figure 1B-C). The first cellular component,
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niejszym czynnikiem prognostycznym. W przedstawianym przypadku potencja∏ proliferacyjny by∏ niski, podobnie jak w kilku
innych doniesieniach, gdzie równie˝ dosz∏o do rozsiewu choroby drogà p∏ynu mózgowo-rdzeniowego. Przedstawiany chory od-
niós∏ korzyÊç z radioterapii. Wi´kszoÊç danych z piÊmiennictwa potwierdza pozytywnà rol´ radioterapii w leczeniu tego nowo-
tworu w przypadkach nieradykalnej resekcji i w razie progresji lub nawrotu.
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Table I. Antibodies for immunohistochemistry
Antibody (clone) Source Type
Synaptophysin (SY38) Boehringer-Mannheim m
GFAP Dako P
Neurofilament Protein (RMD020) Zymed m
Neu-N (MAB 377) Chemicon m
Ki67/MIB1 AMAC m
Abbreviations: m mouse monoclonal; p polyclonal; GFAP Glial
Fibrillary Acidic Proten
409
Figure 1. Histopathology of the presented intraventricular tumor. A) The predominant component of the tumor is a population of medium-size cells with
centrally placed round nuclei in cell bodies which are often clear in H&E stains, ie the typical picture of “oligodendroglioma-like” tumor cells
characteristic of central neurocytomas. H&E, original magnification 358x. B) Scattered throughout the tumor are larger neurons – ganglion cells. H&E,
original magnification 358x. C) In small foci the ganglion cells are more numerous. H&E, original magnification 358x. D) The finely fibrillary tumor
background contains a few eosinophilic granular bodies (arrow). H&E, original magnification 726 x.
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Figure 2. Immunostains of the intraventricular tumor. A) A synaptophysin immunostain shows a diffuse granular immunopositivity in a neuropil
pattern. Original magnification 726x. B) In foci the neuropil pattern of synaptophysin immunopositivity is not very dense, and single ganglion cells with
perikaryal surface immunopositivity (arrow) are apparent. Original magnification 726x. C) In other areas the background synaptophysin immunoreactivity
is very dense, but the clusters of larger neurons still have discernible surface perikaryal immunoreactivity (arrows). Original magnification 726x. D)
Neurofilament protein (antibody RMDO20) immunostains show that many of the larger neurons have cytoplasmic immunopositivity. Original
magnification 358x. E) A few of the smaller neurocytoma cells are also RMDO20 immunopositive. Original magnification 358x. F) An MIB1
immunostain shows a low labeling index (2.7% actual count of multiple fields). Original magnification 726x.
the neurocytic cells, had the usual resemblance to “oligo-
dendroglioma". There was no vascular hyperplasia, and no
definite necrosis. There were scattered eosinophilic gran-
ular bodies among the tumour cells (Figure 1D).
There was almost no GFAP (glial fibrillary acidic
protein) immunopositivity in the tumour, except at the
edges, which contained gliotic brain tissue. There was
a strong diffuse granular immunoreactivity with antibody
to synaptophysin (Figure 2A-C). Additionally, the large
neuronal cells (ganglion cells) were, almost uniformly,
surrounded by a densely granular synaptophysin
immunopositivity on the perikaryal surfaces, while the
cell body cytoplasm was immunonegative (Figure 2B-C).
An immunostain with the antibody RMD020, identify-
ing intermediate molecular weight neurofilament pro-
tein, marked the cytoplasm of most or all of the large
ganglion cells, many axons, and a few of the smaller
“oligodendroglioma”-like cells (Figure 2D-E). Antibody
Neu-N (a neuronal nuclear antigen) was mostly negative;
however, there were rare positive nuclei. An MIB1
immunostain (Ki67) showed a low proliferative index
(2,7%), in accordance with the low grade appearance of
the tumour (Figure 2F).
Finally, the combination of the histopathologic pat-
terns and the immunophenotypes pointed to the diagno-
sis of a low grade neuronal neoplasm of mixed ganglion
cell and neurocytoma cell elements – “ganglioneurocy-
toma".
C l i n i c a l  c o u r s e  a n d  p o s t o p e r a t i v e
r a d i o t h e r a p y
One month later the patient was evaluated by a radia-
tion oncologist with a diagnosis of ganglioneurocytoma
subtotally removed, with a Karnofsky Performance Status
score of 80, a moderate weekness of the extremities more
pronounced on the left, without headache and other neu-
rological abnormalities. In view of the usual good prog-
nosis of the diagnosed tumour an MRI examination was
performed before the final treatment decision. MRI of
the brain revealed an approx. 5 cm tumour in the prima-
ry location with a dissemination of the disease along ven-
tricular walls; and two other tumour masses, one in the
right temporal horn and another in the right occipital
horn. Lumbar CSF cytology was negative for malignant
cells. The neurological condition of the patient rapidly
deteriorated, with an aggravation of generalized weak-
ness and the emergence of a definite left hemiparesis.
The patient had episodes of frank lethargy. Steroid
administration was started and an irradiation of the whole
brain and the 2 first cervical spinal segments was given to
a dose of 42 Gy in 15 fractions. A boost of 4 Gy in two
fractions was added to the primary site of the tumour.
The patient required steroids throughout the duration
of radiotherapy, as the neurological problems aggravated
in the early phases of treatment. MRI of the brain per-
formed 1 month after radiotherapy revealed the disease
to be stable. The general and neurological state of the
patient improved. Steroids were progressively reduced
and, ultimately, stopped. Four months after radiotherapy
the neurological improvement persists.
Discussion
We have described the clinical and pathological features
of a case of an intraventricular tumour in the classic loca-
tion at the foramen of Monroe – central neurocytoma, as
first described by Hassoun et al. and subsequently verified
by many others [1, 3]. Histopathologically, two cell types
were found in the tumour. The predominant one was
identical to the usual “oligodendroglioma-like” of cen-
tral neurocytomas. While this histopathological pattern in
a tumour from this location should be expected to result
in a diagnosis of central neurocytoma, the final diagnosis
as neurocytoma depends on either ultrastructural or
immunohistochemical verification of neuronal differen-
tiation of the tumour cells – specifically positive immunos-
tains for synaptophysin and other neuronal antigens such
as neurofilament protein and Neu-N. Given the tendency
for histological misdiagnosis based on the H&E appear-
ance of tumors resembling “oligodendroglioma”, the actu-
al number of central neurocytomas has almost certainly
been historically underreported.
The second type of neoplastic cells in this tumor
comprised large, often dysplastic or atypical, neurons
(ganglion cells). These had the typical immunopheno-
typic profile of neoplastic ganglion cells, including the
typical perikaryal surface immunopositivity for synapto-
physin [13]. Although WHO brain tumours classification
does not recognise ganglioneurocytoma as a distinctive
entity, there were several pathologic and clinical reports
claiming its approval as a separate tumour of the neu-
ronal origin [8, 10]. For others the presence of ganglionic
differentiation in neurocytomas, which has no demon-
strable prognostic significance (in the small number of
reported cases), should not be cause to recognize a dis-
tinctive type of tumour, but as a morphological type or
variation within the category of central neurocytoma [6].
Future editions of the WHO classification of brain
tumours will have to take these controversies into con-
sideration.
Early descriptions of central neurocytomas consid-
ered these tumours as “benign” lesions. One of the two
described cases in the report of Hassoun et al. died 14
months after surgery, apparently from meningitis, without
evidence of tumor progression in CT exams; MRI was
not available at that time, and no autopsy was performed
[1]. While the WHO classification of brain tumours has
agreed with this “benign” characterization of neurocy-
tomas, there are multiple reports showing a rather dif-
ferent, more aggressive clinical course in some patients,
with local rapid progression or craniospinal dissemina-
tion [4-7]. The initial pathologic appearance of the
tumour in the case we have presented was that of a low
grade neurocytomatous neoplasm, but clinically this was
regarded as a prediction of a “benign” clinical course
of the disease. Atypia, vascular proliferation, pleomor-
phism, and necrosis were absent. Additionally, an MIB1
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immunostain showed a low labelling index, indicating
a low proliferative potential of the tumour. Despite this,
the tumour followed the aggressive course we have
described. It is of crucial importance to find prognostic
factors allowing more accurate predictions of the clinical
behaviour of tumours such as this, which seem uncom-
monly, but not extremely rarely, unpredictable to date.
While a high proliferative index estimated by Ki67
immunostains predicts a poor prognosis according to
some reports [6-7, 14-15] our present case is not the only
reported example of unfavourable clinical course with
craniospinal dissemination of a central neurocytoma
despite a low proliferative index and the absence of other
aggressive histopathological features [3] Others have
reported local recurrences not predicted by histopatho-
logical features ("anaplasia") or proliferation measure-
ment [16]. Other potential prognostic factors, such as age
[6] might be relevant to our case (the patient was 45 years
old) but this has not been a consistent finding among
reported cases either.
The generally accepted treatment of choice for intra-
ventricular neurocytomas is complete surgical resection.
No patient undergoing gross total resection recurred in
the two reported series of 10 and 14 patients, respective-
ly [6, 17], but in another series of 15 patients 3 had symp-
tomatic recurrences following gross total excision [7]. The
role of postoperative radiotherapy for incompletely
resected tumours has been debated. Radiosensitivity of
neurocytomas has been shown in retrospective series [17,
18]. Schild et al. [17] reported 100% 5-year local control
rate for patients irradiated after incomplete resection, in
comparison with 50% for those who did not undergo
postoperative radiotherapy. The latest data support the
use of stereotactic radiosurgery for incompletely resected
tumours which show any sign of progression after surgery
[18, 19]. In our case “extended field” radiotherapy was
used, due to dissemination of the disease in the brain.
The radiotherapy delivered in the presented case stopped
the rapid disease progression and was certainly beneficial,
at least on a short term basis. This observation supports
other data suggesting a useful role of radiotherapy in this
disease. Rapid cerebral dissemination of the disease could
also be an indication for the use of chemotherapy.
Brandes et al. [20] have reported 3 cases of recurrent
neurocytoma with long term disease stabilisation after
a chemotherapy regimen containing cisplatin, etoposide
and cyclophosphamide. In our case the poor general sta-
tus of the patient was thought to preclude the use of
chemotherapy at the time of diagnosis of dissemination.
Chemotherapy remains advisable in case of recurrence
after radiotherapy.
Conclusions
The presented case of ganglioneurocytoma (central neu-
rocytoma with diffuse ganglionic differentiation) is
an example of an unusual, but not unprecedented,
unfavourable clinical course of this disease. Our review of
the literature shows that the course of intraventricular
ganglioneurocytoma or central neurocytoma is not pre-
dictable at the present day and merits further study.
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